Articles tagged with Cancer Medication
A review of cannabinoids suggests they can stop cancer cells from dividing and invading normal tissue. Cannabinoids may also enhance the immune response against tumor growth and spread, providing potential new treatment options for cancer patients.
Leukemia cells infiltrate the central nervous system by grabbing onto laminin proteins and zipping down into the meninges region where cerebral spinal fluid circulates. This discovery arms researchers with new ways to target this pathway and potentially shut it down.
Researchers at Dana-Farber Cancer Institute found biomarkers in melanoma that can help tailor immunotherapy treatments. The study suggests that some patients with advanced melanoma may not benefit from combination therapy, but could do well with single-agent treatment.
Researchers investigating genetic and environmental factors contributing to aggressive prostate cancer in African-American men, a population with a 15% lifetime risk compared to 10% for white men.
The RESPOND study, funded by $26.5 million grants, aims to understand why African-American men are at higher risk for developing aggressive forms of prostate cancer. Researchers will assess social stressors and genetics to identify genetic markers for the disease.
A team of international researchers has mapped the family trees of cancer cells in AML to understand its response to enasidenib and how it can be combined with other anti-cancer drugs. The study provides clues about how AML cells become resistant to therapy and may help design future therapy trials.
Yale Cancer Center scientists have found that rare inherited cancer syndromes are driven by a breakdown in how cells repair their DNA. They suggest using PARP inhibitors to treat these conditions.
Researchers found that omega-3 fatty acid metabolites, called endocannabinoids, can slow tumor growth and inhibit cancer cell migration in mice with osteosarcoma. These molecules were also shown to kill cancer cells, but not as effectively as other chemotherapeutic drugs.
Researchers developed a method to create 3D cultures of clustered cancer cells that better mimic tumors, enabling more accurate drug testing. A new NIH grant will model the response of colon cancer cells to anticancer drugs, aiming to identify molecular mechanisms of drug resistance and develop new treatment strategies.
Researchers developed a technique to measure drug-target engagement in individual cancer cells, revealing variation in effectiveness between cells within a tumour. The findings could help clinicians choose the best course and delivery of treatment for cancer patients, improving treatment outcomes.
Researchers at the University of Zurich have developed a new method to quickly test various anti-cancer drugs and treatment combinations at the cellular level. The approach has revealed how PARP inhibitors work in cancer cells by locking their target protein in an inactive state, leading to DNA damage and cell death.
A University of Colorado Cancer Center study found that brain metastases are a common occurrence in stage IV ROS1-positive non-small cell lung cancer. The study also showed that patients with ROS1 mutations had similar progression-free survival rates as ALK patients when treated with crizotinib, but with a higher risk of brain metastas...
A Phase 1b clinical trial has demonstrated that the combination of tucatinib and T-DM1 can control median 8.2 months in heavily pretreated HER2-positive breast cancer patients, with 48% response rate. The drug also shows efficacy against brain metastases, a major cause of mortality from the disease.
A new UK-based institute at the University of Cambridge is using cutting-edge analytics to maximize the use of big data sets in cancer patient care. The Mark Foundation Institute for Integrated Cancer Medicine aims to integrate clinical, genomic, and image data to inform treatment decisions.
A team of leukemia scientists has discovered how to predict healthy individuals at risk of developing acute myeloid leukemia (AML) by identifying genetic mutations in their blood. By analyzing data from a large population health study, the researchers found that people with early mutations are more likely to develop AML.
Researchers reveal curcumin binds to and inhibits DYRK2, impairing cell proliferation and reducing cancer burden. Curcumin's effectiveness may be limited due to its rapid expulsion from the body.
Researchers have identified a new target for treating certain types of leukemia by exploiting an existing FDA-approved drug, Ibrutinib. This discovery could provide another treatment option for patients and accelerate clinical trials.
A cost-effectiveness study analyzed risk-based breast cancer screening programs versus standard age-based screening, evaluating their impact on healthcare resources and patient outcomes. The study found that risk-based screening programs can be more cost-effective than traditional age-based programs for certain populations in the UK.
Researchers have found that cancer stem cells exist in multiple states and can change form, making them resistant to treatment. By targeting cell metabolism, they may be able to kill these stem cells, potentially opening up a new approach to cancer therapy.
A new computer algorithm developed by Johns Hopkins researchers can predict when cancer cells will develop resistance to treatment. The Coordinate Gene Activity in Pattern Sets (CoGAPS) algorithm uses in vitro cell models and computational analysis to track molecular changes over time.
Researchers at Brigham and Women's Hospital have developed a supramolecular therapeutic that blocks the 'eat me not' signal sent by cancer cells and converts macrophages to the attacking M1 subtype. The approach has yielded promising results in preclinical models, showing complete inhibition of tumor growth and increased survival rates.
Scientists at Scripps Research found that several existing FDA-approved anti-cancer drugs bind tightly to RNA, modulating targets and causing some effects. The discovery offers a promising new approach for tackling diseases considered undruggable, including ALS and certain cancers.
A new study finds that enzalutamide significantly lowers the risk of metastasis or death in men with non-metastatic castrate-resistant prostate cancer, delaying cancer re-appearance by almost two years. The drug also shows a 71% lower risk of metastasis or death compared to placebo.
Researchers discovered a molecular inhibitor that could help fight prostate cancer when resistance develops to CDK4/6 inhibitors. The study found that tumors become more aggressive and dependent on the MAPK-6 pathway when resistance occurs, making MEK inhibitors a potential therapeutic option.
A new study found that an experimental drug called AZ32 selectively sensitizes brain tumors to radiation, extending the survival of mouse models with human glioblastoma multiforme. The combination therapy forced GBM cells to undergo mitotic catastrophe, leading to cell death.
Gambhir's work on multimodality molecular imaging has advanced nuclear medicine and healthcare. He has developed strategies to study gene and cell therapies, and his lab has more than 625 publications and over 40 patents pending.
Sanford Burnham Prebys Medical Discovery Institute has received four Padres Pedal the Cause collaborative grants to fund research projects in cancer and immunology. The projects aim to develop new insights into developing drugs and treatments designed to attack and kill cancer cells.
Researchers discover a protein that shields the PI3K pathway from targeted drugs, leading to improved efficacy with combination therapy. A new study reveals that blocking this protein restores cancer-killing potential in previously ineffective therapies.
Researchers have discovered a new type of small-cell lung cancer (SCLC) with distinct biological signatures, paving the way for developing personalized treatments. The discovery involves a novel transcription factor called POU2F3, which is expressed in a specific subset of SCLC tumors and may be targeted by specific drugs.
Researchers at EMBL screened over 1100 treatment conditions using a novel microfluidic device, discovering individualized cancer therapies for each patient. The device was tested on four patient biopsies, showing highly reproducible results and potential for personalized medicine.
A research team, led by OHSU physician-scientists, has discovered a drug compound that inhibits cancer cell movement and prevents them from spreading throughout the body. The compound was developed using a multidisciplinary approach, combining chemistry and biology to create a highly effective therapeutic.
Researchers at Texas Biomedical Research Institute have repurposed promising cancer chemotherapy drugs to target tuberculosis (TB), a deadly disease that kills four people every minute. The study found that these experimental drugs can reduce TB growth by 80% and also decrease inflammation and damage to the lungs.
A new study from the University of Pittsburgh School of Pharmacy found that concurrent opioid and benzodiazepine use increases the risk of opioid-related overdose by five-fold compared to opioid-only use. The risk decreases after 180 days of concurrent use, but is still elevated compared to opioid-only use.
A research team at the Walter and Eliza Hall Institute identified the molecular trigger for necroptosis, a type of controlled cell death that can lead to diseases like stroke, organ transplant injury, and kidney disease. The discovery could lead to new therapeutic targets for treating cancer and immune disorders.
Recent advances in cancer research focus on inhibiting key enzymes in glycolysis and glutaminolysis pathways to slow cancer cell proliferation. Several inhibitors are being tested in clinical trials, offering a promising new approach to combat cancer.
Monash researchers have created a computer model that can predict which combination of drugs will be most effective in treating triple negative breast cancer. The model, developed using genetic and treatment data from hundreds of patients, reveals a previously unknown combination of two drugs that may be successful.
Scientists discovered genetic causes of a group of related infant cancers that are targetable by existing drugs used to treat lung cancer and melanoma. Researchers identified mutations in the Epidermal Growth Factor Receptor (EGFR) and BRAF genes, which can be treated with afatinib and other targeted agents.
A novel combination of an epigenetic drug and a BCL-2 inhibitor has been identified as a promising target to reverse the development of high-risk neuroblastoma. The study found that this combination increases cell differentiation, allowing cancer cells to mature normally, making them more vulnerable to treatment.
Researchers found that glutamine is not a primary fuel for NK cells, but rather glucose. This discovery has significant implications for cancer therapies under development by pharmaceutical companies.
Researchers at FAU have successfully developed proteins that function like a shuttle to release medication directly in the body where it's needed. This breakthrough could enable targeted and tissue-specific administration of medication in future, potentially lowering doses and reducing side effects.
Researchers found that PARP inhibitors, such as rucaparib, showed promise in treating pancreatic cancer in patients with BRCA mutations. In a small study, 32% of patients experienced disease control after treatment.
Researchers found a link between calcitriol and reduced ovarian cancer progression by blocking smad signaling in tumor cells and supportive fibroblasts. The study opens a new potential avenue for treating ovarian cancer, with calcitriol already FDA-approved for other uses.
A recent study published in BMJ Open found that 7.6% of Britons reported experiencing preventable harm in primary care, with doctors often failing to take concerns seriously. The survey, conducted by University of Manchester researchers, highlights a significant divide between patient and clinician perspectives.
Researchers at Temple University Health System discover a dual synthetic lethality approach to eradicate cancer cells by inhibiting two backup repair pathways simultaneously. The strategy effectively narrows down the number of secondary repair pathways available, helping to ensure cancer cell eradication.
A new study found that CRISPR-Cas9 gene editing can activate the p53 protein, which reduces the efficiency of gene editing but also contributes to cancer cell growth. Researchers recommend further studies to improve safety for CRISPR-based therapies.
The University of Texas MD Anderson Cancer Center's Therapeutics Discovery team has developed a drug called IACS-10759, which targets metabolic vulnerability in cancer cells. The drug, an inhibitor of oxidative phosphorylation, shows promise for treating acute myeloid leukemia and solid tumors.
Researchers found that long-term viral suppression significantly reduces cancer risk in aging HIV-positive individuals, with lower rates seen in patients with sustained suppression compared to those with early or no suppression. The study highlights the importance of viral suppression in preventing cancer and may inform strategies for ...
Researchers have developed a new epigenetic drug that slows down cell growth in Mantle Cell Lymphoma by inhibiting the HDAC6 gene. The substance shows high efficacy in cultured cells, murine studies and patient-derived cells with minimal toxicity to healthy cells.
Vanderbilt University has received a five-year, $8.1-million grant from the National Cancer Institute to study small cell lung cancer, a highly aggressive and incurable tumor. The new center will use a multidisciplinary approach combining experimentation, mathematical modeling, and machine learning to develop new treatment avenues.
Researchers investigating combination therapies have encountered disappointing results. However, experts advocate for well-planned, randomized mid-stage trials to increase the chances of successful combined immunotherapies before Phase III trials.
Scientists have found that drug-resistant cancer cells have longer antennae-like structures called cilia, which can be targeted to restore sensitivity to treatment. Blocking growth of cilia restored cells' response to cancer drugs, with nearly doubling effectiveness.
Researchers at University of Groningen have elucidated the 3D structure of ASCT2, an amino acid transporter involved in various cancers. The study provides new insights into the protein's mechanism and potential targets for drug development.
A clinical trial shows that an immune checkpoint inhibitor can shrink tumors in nearly half of patients with advanced cutaneous squamous cell carcinoma. The drug, cemiplimab, works by blocking PD1, a surface receptor on T cells that shuts down immune response to cancer.
By replacing cysteine with selenocysteine, researchers have created biologically stable proteins that can survive longer in the human body. This breakthrough could lead to smaller, less frequent doses of medicine, lower healthcare costs, and fewer side effects for patients with cancer and other diseases.
The NCI-MATCH trial has released new findings on three arms of the trial, showing promise in patients with rare genetic changes. The study's results suggest that future studies could see more responses in populations with earlier-stage disease.
Researchers at Virginia Commonwealth University have discovered a mechanism that protects glioblastoma multiforme (GBM) stem cells from programmed cell death. The study found that protective autophagy is regulated by the gene MDA-9/Syntenin, and inhibiting this process can lead to cancer cell death.
A Phase II trial suggests that erdafitinib, an FGFR inhibitor, benefits patients with metastatic urothelial cancer harboring FGFR3 mutations. The therapy achieved a 40% overall response rate, including complete and partial responses, as well as stable disease in nearly half of patients.
Updated phase 1 clinical trial results of crizotinib against MET-amplified non-small cell lung cancer show a 40 percent response rate and 6.7-month median progression-free survival. The study defines new criteria to define 'highly MET-amplified' cancer, suggesting that crizotinib may benefit more patients than previously thought.
A Phase I trial shows ivosidenib, a protein inhibitor drug, is safe and effective for treating acute myeloid leukemia (AML) patients with IDH1 mutations. The study achieved an overall response rate of 41.6% and complete remission rates of 21.6%, with improved survival rates at 18 months compared to historical controls.
A phase 1 trial of ivosidenib against IDH1+ acute myeloid leukemia (AML) achieved an overall response rate of 41.9% and median progression-free survival of 8.2 months. Twenty-four percent of patients reached a complete response.